Terns Pharmaceuticals (TERN): +18% Surge in 30 Days on Merck's $53 Acquisition Deal

Key Takeaways

• TERN stock rose approximately +18% over the last 30 days, primarily driven by Merck's March 25 announcement of a $53 per share acquisition deal, representing a substantial premium to prior trading levels.
• Over the past quarter, shares surged +48%, fueled by building momentum in oncology pipeline updates and culminating in the transformative buyout agreement.
• Key catalysts include the Merck tender offer commencement, positive Q4 2025 earnings beat, and investor focus on TERN-701, a promising allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML).
• Post-announcement trading has been range-bound near the deal price amid tender offer progress and regulatory reviews.
• Sector sentiment in biotech M&A (mergers and acquisitions) has supported the uptrend, with the stock near its 52-week high of $53.19.

Terns Pharmaceuticals (TERN): Company Overview and Market Position

Terns Pharmaceuticals, Inc. (TERN) is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for oncology and obesity. The company's core business model centers on advancing internally discovered therapies with de-risked mechanisms to address large unmet needs in serious diseases.

Key pipeline assets include TERN-701, a highly selective oral allosteric BCR-ABL tyrosine kinase inhibitor (TKI) in Phase 1/2 trials for chronic myeloid leukemia (CML), a bone marrow cancer; TERN-501, a thyroid hormone receptor beta (THR-β) agonist in Phase IIa for metabolic dysfunction-associated steatohepatitis (MASH); and the TERN-801 series of glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

In the competitive biotechnology industry, Terns holds a strong position in next-generation oncology treatments, particularly with TERN-701's potential to improve efficacy and safety over existing TKIs. From what I see, this pipeline exposure directly explains the recent stock strength, as acquisition interest highlights the value of its hematology innovations amid broader biotech consolidation.

TERN Stock Performance: 30-Day and Quarterly Review

Over the last 30 days, TERN stock climbed +18%, from a close of around $44.29 on March 11, 2026, to approximately $52.56 as of April 9, 2026. The movement was volatile and trend-driven, with a sharp surge following the March 25 acquisition announcement, pushing shares toward the $53 deal price, followed by consolidation near recent highs.

For the past quarter, shares advanced +48%, starting from about $35.48 around January 9, 2026. Performance featured steady gains building through pipeline updates and earnings, accelerating into a steep rally post-buyout news, reflecting strong momentum in a high-volume environment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Key Drivers Behind TERN's 30-Day Gain

The primary catalyst was Merck's March 25, 2026, announcement of a definitive agreement to acquire Terns for $53 per share in cash, valuing the equity at $6.7 billion—a 31% premium to the 60-day volume-weighted average price (VWAP) and 42% to the 90-day VWAP. This deal, aimed at bolstering Merck's oncology pipeline ahead of Keytruda patent cliffs, propelled shares upward, with the stock quickly approaching the offer level.

Supporting factors included a Q4 2025 earnings beat on April 2, reporting EPS of -$0.24 versus consensus -$0.30, alongside cash reserves providing runway. Analyst attention on TERN-701's Phase 1/2 progress and tender offer commencement on April 7 further sustained sentiment, keeping price action range-bound but elevated. One thing that stands out is how these elements aligned to maintain the elevated price levels.

Quarterly Performance Drivers for TERN

The quarter's +strong performance stemmed from sustained narratives around Terns' oncology pivot, with earlier metabolic assets deprioritized for partnering. Institutional buying, such as Boxer Capital's position buildup, and index inclusion notices built momentum into March.

The Merck acquisition overshadowed prior catalysts like refreshed corporate presentations highlighting TERN-701 milestones and Q3 2025 earnings beats. Broader biotech M&A trends and oncology demand, amid favorable macro conditions for clinical-stage assets, amplified institutional interest, culminating in the deal-driven rally. In my view, this combination of factors made the quarter particularly compelling for TERN investors.

Trending AI Robots

I regularly check Tickeron’s Trending AI Robots page, which showcases the platform's top-performing AI trading bots from among hundreds that trade thousands of tickers across various markets. This curated section highlights bots with the strongest recent track records, relevance to current market trends, and diverse strategies—ranging from short-term scalping and momentum plays to longer-term trend following and mean reversion approaches. Performance metrics such as win rate, average return per trade, Sharpe ratio, and maximum drawdown are transparently displayed, helping me assess risk-adjusted results across different timeframes like intraday, daily, or weekly. Whether focusing on equities, ETFs, or options, these bots leverage advanced machine learning to adapt to volatility and sentiment shifts. I find it useful to explore the page to identify bots aligning with my trading style and consider integrating them into my strategy for automated, data-driven decisions.

What's Next for TERN: Key Forecast Drivers

I'm watching progress on the Merck tender offer, set to expire May 4, 2026, including tender levels exceeding 50% and Hart-Scott-Rodino antitrust clearance, with closure eyed for Q2 2026. Updates on TERN-701's Phase 1/2 CARDINAL trial data could influence sentiment pre-close.

Industry trends in oncology M&A and CML treatment evolution remain key, alongside any regulatory feedback or competing bids. Macro factors like interest rates impacting biotech funding and overall sector valuations warrant attention. Risks include deal delays or antitrust hurdles, while catalysts may arise from pipeline advancements or strategic partnering of metabolic assets. This is important because it shapes the near-term outlook for TERN.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.

Contributor

Alicia|Beginner